SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

04 Nov 2025 Evaluate
The Revenue for the quarter ended  September 2025 of Rs. 12202.40 millions grew by 8.09 % from Rs. 11289.10 millions.Modest increase of 6.19% in the Net Profit was reported from. 2349.80 millions to Rs. 2495.30  millions.The company reported a good operating profit of 3646.20 millions compared to 3432.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 12202.40 11289.10 8.09 24288.00 22061.80 10.09 43220.40 39711.20 8.84
Other Income 750.30 403.40 85.99 1156.60 687.10 68.33 1198.70 1164.80 2.91
PBIDT 3646.20 3432.50 6.23 7346.50 6874.50 6.87 13245.90 12359.10 7.18
Interest 7.30 7.30 0.00 14.60 14.50 0.69 46.00 68.00 -32.35
PBDT 3638.90 3425.20 6.24 7331.90 6860.00 6.88 13199.90 12291.10 7.39
Depreciation 419.20 333.20 25.81 822.30 662.40 24.14 1399.30 1321.60 5.88
PBT 3219.70 3092.00 4.13 6509.60 6197.60 5.03 11800.60 10969.50 7.58
TAX 724.40 742.20 -2.40 1464.60 1487.50 -1.54 2631.70 2897.10 -9.16
Deferred Tax 64.70 30.90 109.39 97.60 62.00 57.42 51.40 121.30 -57.63
PAT 2495.30 2349.80 6.19 5045.00 4710.10 7.11 9168.90 8072.40 13.58
Equity 250.70 250.70 0.00 250.70 250.70 0.00 250.70 252.70 -0.79
PBIDTM(%) 29.88 30.41 -1.72 30.25 31.16 -2.93 30.65 31.12 -1.53

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×